Dipeptidyl Peptidase Inhibitor

Dipeptidyl Peptidase Inhibitors (59):

Cat. No.	Product Name	Effect	Purity

HY-15981

Omarigliptin	Inhibitor
Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction.

HY-14806

Teneligliptin	Inhibitor	99.85%
Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM.

HY-A0023

Alogliptin Benzoate	Inhibitor	99.99%
Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC₅₀ of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.

HY-A0023A

Alogliptin	Inhibitor	99.92%
Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC₅₀ of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.

HY-14892A

Gemigliptin tartrate	Inhibitor	98.17%
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.

HY-117985A

Evogliptin hydrochloride	Inhibitor
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.

HY-161428

ZINC000003015356	Inhibitor
ZINC000003015356 is a DPP4 inhibitor.

HY-10289

Carmegliptin	Inhibitor
Carmegliptin is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a substrate of P-glycoprotein that synergizes with Verapamil (HY-14275). Carmegliptin improves insulin sensitivity and reduces hepatic glucose production in hyperglycemic mice. Carmegliptin is promising for research of type 2 diabetes, hypertension and cardiovascular disease.

HY-111174A

Diprotin A TFA	Inhibitor	99.55%
Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).

HY-15408A

Trelagliptin succinate	Inhibitor	99.96%
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).

HY-14806A

Teneligliptin hydrobromide	Inhibitor	99.99%
Teneligliptin (MP-513) hydrobromide is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM.

HY-108319

DPP-IV-IN-2	Inhibitor	≥98.0%
DPP-IV-IN-2 is an inhibitor of both dipeptidyl peptidase IV (DPIV) and DP8/9 with IC₅₀s of 0.1 and 0.95 μM, respectively.

HY-112668A

Retagliptin	Inhibitor	98.51%
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research.

HY-101769

UAMC00039 dihydrochloride	Inhibitor	99.81%
UAMC00039 dihydrochloride is a potent, reversible and competitive dipeptidyl peptidase II inhibitor with an IC₅₀ of 0.48 nM.

HY-10286

Dutogliptin	Inhibitor	99.32%
Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.

HY-16448

Saxagliptin hydrochloride	Inhibitor	99.71%
Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research.

HY-112668

Retagliptin phosphate	Inhibitor	99.89%
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research.

HY-14291A

Vildagliptin dihydrate	Inhibitor
Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity.

HY-13233

Talabostat	Inhibitor
Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC₅₀ < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC₅₀ = 560 nM), inhibits DPP8/9 (IC₅₀ = 4/11 nM; K_i = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC₅₀ = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities.

HY-124958

NDMC101	Inhibitor	99.91%
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.

Name
Email *

	Sorry, but the email address you supplied was invalid.